📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
NCLT Dismisses DBS Bank's Claim Against Orchid Pharma for CIRP Lease Rent
The National Company Law Tribunal (NCLT), Chennai Bench, has dismissed an application filed by DBS Bank (formerly Lakshmi Vilas Bank) against Orchid Pharma. The bank was seeking payment for lease rent and Insolvency Resolution Process Costs incurred during the company's CIRP period. The order, pronounced on April 2, 2026, and made available on April 10, 2026, rules in favor of Orchid Pharma. The company has confirmed that this dismissal results in nil financial impact on its operations.
Key Highlights
NCLT Chennai Bench dismissed Interim Application IA(IBC)/784/CHE/2020 filed by DBS Bank.
The claim involved lease rent dues and Insolvency Resolution Process Costs during the CIRP period.
The order was officially made available on April 10, 2026, following a pronouncement on April 2, 2026.
Orchid Pharma confirmed that the dismissal of this claim has nil financial or operational impact.
💼 Action for Investors
This is a positive development as it removes a legacy legal hurdle and potential contingent liability from the company's insolvency period. Investors can view this as a sign of strengthening corporate clarity, though it does not change immediate earnings fundamentals.
Loading analysis...
CARE Ratings Downgrades Orchid Pharma's Long-Term Rating to 'BBB+'; Outlook Stable
CARE Ratings has downgraded Orchid Pharma's long-term bank facilities rating from 'CARE A-' to 'CARE BBB+' with a stable outlook. The rating agency also removed the company from 'Rating Watch with Developing Implications' following a review of its FY25 and 9MFY26 financial performance. While short-term ratings for facilities worth Rs. 84 crore were reaffirmed at 'CARE A2', the overall downgrade affects total bank facilities amounting to Rs. 366.50 crore. This revision reflects the agency's updated assessment of the company's credit profile and operational developments.
Key Highlights
Long-term bank facilities of Rs. 207.50 crore downgraded from CARE A- to CARE BBB+.
Short-term ratings for Rs. 84.00 crore reaffirmed at CARE A2.
Total bank facilities reviewed by CARE Ratings amount to Rs. 366.50 crore.
Company removed from 'Rating Watch with Developing Implications' and assigned a 'Stable' outlook.
Rating action based on FY25 audited and 9MFY26 provisional financial performance and pending NCLT orders.
💼 Action for Investors
Investors should exercise caution as a credit downgrade typically indicates a perceived increase in credit risk or weakening financial metrics. Monitor the company's upcoming earnings reports to assess if operational cash flows are sufficient to service debt obligations.
Loading analysis...
Orchid Pharma Merger Update: NCLT Reserves Order for Amalgamation with Dhanuka Laboratories
Orchid Pharma Limited has announced that the National Company Law Tribunal (NCLT) has reserved its order for the Scheme of Amalgamation with Dhanuka Laboratories Limited as of March 18, 2026. This merger involves the integration of the promoter entity, Dhanuka Laboratories, into Orchid Pharma. The formal pronouncement of the order is the final step before the merger becomes effective. Investors are awaiting the specific details of the order to understand the impact on the company's capital structure.
Key Highlights
NCLT has reserved the final order for the merger of Dhanuka Laboratories with Orchid Pharma on March 18, 2026.
The amalgamation process is being carried out under Regulation 30 of SEBI Listing Regulations.
Dhanuka Laboratories is the Amalgamating Company, while Orchid Pharma is the Amalgamated Company.
The company will notify stock exchanges and shareholders once the formal written order is received.
💼 Action for Investors
Investors should maintain a watch on the stock as the formal NCLT order pronouncement is imminent. The merger is a significant corporate restructuring that could impact the company's valuation and operational efficiency.
Loading analysis...
Orchid Pharma Q3 FY26 Sales Down 5%, EBITDA Plummets 65% with Net Loss of ₹6 Cr
Orchid Pharma reported a weak performance for Q3 FY26, with standalone sales declining 5% year-on-year to ₹207 crore. The company's EBITDA saw a significant drop of 65%, falling to ₹13 crore, primarily due to a sharp contraction in gross margins from 43% to 31%. Consequently, the company posted a net loss of ₹6 crore for the quarter compared to a profit of ₹24 crore in the same period last year. For the nine-month period, sales are down 16% and EBITDA has halved, indicating sustained operational pressure.
Key Highlights
Standalone sales for Q3 FY26 fell to ₹207 crore from ₹217 crore in Q3 FY25, a 5% decline.
EBITDA margins contracted sharply to 6% in Q3 FY26 from 17% in the previous year's quarter.
Reported a net loss (PBT/PAT) of ₹6 crore in Q3 FY26 against a profit of ₹24 crore in Q3 FY25.
Gross margins declined significantly to 31% compared to 43% in the year-ago period due to higher COGS.
9M FY26 performance shows a 16% decline in sales and a 50% drop in EBITDA compared to 9M FY25.
💼 Action for Investors
Investors should exercise caution as the company faces significant margin pressure and declining sales. It is advisable to monitor the management's commentary regarding raw material costs and recovery timelines before making new positions.
Loading analysis...
Orchid Pharma Reports Q3 Net Loss of ₹12.6 Cr; Revenue Dips to ₹207 Cr
Orchid Pharma reported a consolidated net loss of ₹12.61 crore for the quarter ended December 31, 2025, a sharp reversal from a profit of ₹20.78 crore in the same period last year. Revenue from operations declined by 4.6% YoY to ₹207.27 crore. The bottom line was significantly impacted by an exceptional item of ₹7.11 crore related to the implementation of New Labour Codes and higher employee benefit expenses. The company is also in the process of merging its holding company, Dhanuka Laboratories, with the next NCLT hearing scheduled for March 2026.
Key Highlights
Consolidated revenue decreased to ₹207.27 crore in Q3 FY26 from ₹217.34 crore in Q3 FY25.
Reported a consolidated net loss of ₹12.61 crore versus a profit of ₹20.78 crore in the year-ago quarter.
Exceptional charge of ₹7.11 crore recognized due to past service costs under the New Labour Codes effective November 2025.
Consolidated EPS fell to ₹(2.49) from ₹4.10 YoY.
Utilized ₹332.56 crore of QIP proceeds for debt repayment and expansion, with ₹61.98 crore remaining for the Jammu facility.
💼 Action for Investors
Investors should exercise caution as the company has swung into a loss with declining year-on-year revenues. Key monitorables include the completion of the merger with Dhanuka Laboratories and the operationalization of the new Jammu manufacturing facility.
Loading analysis...
Orchid Pharma Q3 Results: Reports Consolidated Net Loss of ₹12.6 Cr; Revenue Dips 4.6% YoY
Orchid Pharma Limited reported a weak performance for the quarter ended December 31, 2025, swinging to a consolidated net loss of ₹12.61 crore from a profit of ₹20.78 crore in the year-ago period. Consolidated revenue from operations declined to ₹207.27 crore, down from ₹217.34 crore in Q3 FY25. The results were further weighed down by an exceptional item of ₹7.11 crore related to employee benefit obligations under the New Labour Codes. On the corporate front, the company's merger with its holding company, Dhanuka Laboratories, is progressing through the NCLT process.
Key Highlights
Consolidated revenue from operations decreased by 4.6% YoY to ₹207.27 crore.
Reported a consolidated net loss of ₹12.61 crore compared to a net profit of ₹20.78 crore in Q3 FY25.
Exceptional item of ₹7.11 crore recognized as past service cost due to the implementation of New Labour Codes.
Utilized ₹332.56 crore of QIP proceeds, with ₹195.46 crore directed toward debt repayment.
Amalgamation with Dhanuka Laboratories Limited is pending NCLT approval, with the next hearing on March 02, 2026.
💼 Action for Investors
Investors should be cautious given the swing to a net loss and declining revenue; focus should remain on the successful integration of the upcoming merger and the operationalization of the Jammu manufacturing facility.